Across TCGA pan-cancer cohorts, LAMA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LAMA2 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LAMA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LAMA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where LAMA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	34	view →
LUAD	OS	Tertile	III,IV	0.330	1.000	.005	19	view →
PDAC	DFS	Tertile	IV	0.934	0.235	.024	10	view →
HNSC	OS	Quartile	II,III,IV	0.914	1.000	.025	2	view →
LSCC	DFS	Median	All	1.000	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LAMA2 tumor-vs-normal RNA expression · all LAMA2 data types